Mutation-Specific Antibodies for the Detection of EGFR Mutations in Non–Small-Cell Lung Cancer
暂无分享,去创建一个
M. Loda | L. Chirieac | T. Gu | Xinmin Zhou | M. Comb | Bradley L. Smith | Jiong Wu | R. Polakiewicz | K. Crosby | L. Sholl | W. Cheung | H. Haack | C. Reeves | Dai-qiang Li | Yi Tan | Y. Tan | B. Smith | J. Yu | G. Innocenti | R. Wetzel | X. Hong | S. Kane | E. Benedettini | W. C. Cheung | M. Ferrante | Tianqi Gu | J. Wu | D. Li | A. Becker | X. Zhou | Gregory Innocenti | Randy Wetzel | A. Becker | Jian Yu | Xiqiang Hong | Michelle Ferrante | Jian Yu
[1] W. Pao,et al. Update on Epidermal Growth Factor Receptor Mutations in Non–Small Cell Lung Cancer , 2006, Clinical Cancer Research.
[2] T. Illig,et al. MALDI‐TOF MS and TaqMan® assisted SNP genotyping of DNA isolated from formalin‐fixed and paraffin‐embedded tissues (FFPET) , 2005, Human mutation.
[3] Patricia L. Harris,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.
[4] S. Gabriel,et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.
[5] A. Godwin,et al. Phase II Study of Gefitinib in Patients with Relapsed or Persistent Ovarian or Primary Peritoneal Carcinoma and Evaluation of Epidermal Growth Factor Receptor Mutations and Immunohistochemical Expression: A Gynecologic Oncology Group Study , 2005, Clinical Cancer Research.
[6] A. Marchetti,et al. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] R. Wilson,et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[8] Alona Muzikansky,et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] Janusz Jankowski,et al. Epidermal Growth Factor Receptor Kinase Domain Mutations in Esophageal and Pancreatic Adenocarcinomas , 2006, Clinical Cancer Research.
[10] Takayuki Kosaka,et al. Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer , 2004, Cancer Research.
[11] E. Vokes,et al. Phase II Trial of Gefitinib 250 mg Daily in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck , 2005, Clinical Cancer Research.
[12] Takayuki Kosaka,et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] William Pao,et al. EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression. , 2008, The Journal of molecular diagnostics : JMD.
[14] M. Maemondo,et al. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] William Pao,et al. Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond , 2008, Modern Pathology.
[16] J. Minna,et al. EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients. , 2005, Cancer research.